右江医学2024，Vol.52Issue(6)：502-507,6.DOI:10.3969/j.issn.1003-1383.2024.06.004
达格列净治疗射血分数保留心力衰竭患者的临床观察
Clinical observation of dapagliflozin in the treatment of patients with heart failure with preserved ejection fraction
摘要
Abstract
Objective To observe the clinical efficacy of dapagliflozin in the treatment of heart failure with preserved e-jection fraction(HFpEF).Methods 126 HFpEF patients who visited the Cardiology Department of Liaocheng People's Hospital from January 2022 to May 2023 were selected and randomly divided into control group and observation group,with 63 cases in each group.The control group were treated with drugs against heart failure and basic diseases,based on which,the observation group were treated with dapagliflozin at a dose of 10 mg per day.And then,N-terminal B-type natriuretic peptide precursor(NT-proBNP),hypersensitive C-reactive protein(hs-CRP),6 min walking distance(6MWD),clinical efficacy as well as cardiac events and adverse drug reactions were observed before and after treatment in the two groups.Re-sults After treatment,the levels of NT-proBNP and hs-CRP in both groups were lower than those before treatment,and those in the observation group were lower than those in the control group(P＜0.05),6MWD was higher than that before treat-ment,and the index in the observation group was higher than that in the control group(P＜0.05).After treatment,the total clinical effective rate of the observation group was 93.6％,which was higher than that of the control group(76.2％)(P＜0.05).The incidence of adverse cardiac events in the observation group was 3.2％,which was lower than that of the control group(15.9％)(P＜0.05).The incidence of adverse drug reactions in the observation group was 6.3％,which was higher than that of the control group(4.8％),but difference was not statistically significant(P＞0.05).Conclusion Dapaglifloz-in can reduce the levels of NT-proBNP and hs-CRP in patients with HFpEF,improve cardiac function,reduce the incidence of adverse cardiac events,and improve exercise endurance.It is safe and effective in clinical application.关键词
达格列净/射血分数保留心力衰竭/心功能/心脏不良事件/预后Key words
dapagliflozin/heart failure with preserved ejection fraction(HFpEF)/cardiac function/cardiac adverse e-vents/prognosis分类
医药卫生引用本文复制引用
郭丽军,张新,刘玉芝,任玉华,李泰..达格列净治疗射血分数保留心力衰竭患者的临床观察[J].右江医学,2024,52(6):502-507,6.基金项目
聊城市重点研发计划项目(2023YD13) （2023YD13）
